Latest National Comprehensive Cancer Network Stories
ST. HELIER, Jersey, Jan. 22, 2013 /PRNewswire/ -- Novocure Limited announced today that Novocure's NovoTTF(TM) Therapy has been added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers. The new NCCN Guidelines® indicate that physicians consider using NovoTTF Therapy as a new option, in addition to surgery, chemotherapy, and radiation, for patients with glioblastoma brain tumors that recur or progress after initial treatment....
AMERICAN CANCER SOCIETY JOINS SCREENING SUPPORTERS WASHINGTON, Jan. 11, 2013 /PRNewswire-USNewswire/ -- Today, in response to the announcement by the American Cancer Society, Lung Cancer Alliance (LCA) President & CEO Laurie Fenton Ambrose said: "We are pleased that the American Cancer Society has joined Lung Cancer Alliance, other leading professional organizations and medical centers around the country in endorsing CT screening for those at high risk for lung cancer." "No one...
SOUTH SAN FRANCISCO, Calif., Jan. 7, 2013 /PRNewswire/ -- Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced that, for the first time, molecular testing is now included in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Thyroid Carcinoma. The new NCCN Guidelines indicate that, when a thyroid nodule fine needle aspiration (FNA) result is indeterminate using...
AUSTIN, Texas, Oct. 17, 2012 /PRNewswire/ -- 1-800-Oncologist, Inc. announced today that Optim Oncology, Inc. has joined its national network of Digital Oncologists(TM). Optim Oncology, a leading provider of cancer care and radiation therapy services, is the largest freestanding oncology practice in Oklahoma with seven locations throughout the state. As a 1-800-Oncologist network affiliate, Optim Oncology has integrated a 'Total Patient Engagement' solution to streamline existing and...
WASHINGTON, Oct. 2, 2012 /PRNewswire/ -- The Community Oncology Alliance (COA) and Vital Options International will host the launch event for a series of Community Cancer Care Advocacy Day Forums. The event will be held in Washington, D.C. on October 24, 2012 and is open to the cancer care community at no charge. Invitations to attend have been sent to organizations within the cancer community including national and grassroots cancer organizations, oncology professionals, cancer...
WASHINGTON, Sept. 14, 2012 /PRNewswire-USNewswire/ -- Today, Lung Cancer Alliance (LCA) praised the decision this week to add lung cancer and other cancers to the list of diseases covered by the James Zadroga 9/11 Health and Compensation Act Fund. The Zadroga fund was established by Congress in 2010 to provide health benefits for the survivors and responders to the 9/11 disaster. Initially cancers were excluded from the diseases covered by the $4.3 billion fund but subsequent review...
TALLAHASSEE, Fla., Sept. 14, 2012 /PRNewswire/ -- The Large Urology Group Practice Association (LUGPA), the Association of Freestanding Radiation Oncology Centers (AFROC) and the Community Oncology Alliance (COA) today united to preserve access for thousands of patients stricken with cancer to life-saving cancer radiation treatments. LUGPA, AFROC and COA submitted commentary to Centers for Medicare & Medicaid Services (CMS) addressing the drastic effect reimbursement cuts to...
WASHINGTON, July 18, 2012 /PRNewswire/ -- The Community Oncology Alliance (COA), a non-profit organization dedicated to preserving and fostering community cancer care, announced that the Oncology Medical Home (OMH) Steering Committee has reached a significant benchmark in the development of the OMH model for cancer care. A list of sixteen quality, value and outcome measures has been approved as a result of the coordinated work by a cross-section of 18 cancer care stakeholders...
IRVING, Texas, June 26, 2012 /PRNewswire/-- Caris Life Sciences(®), a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, today announced the launch of Caris Target Now(TM) Select, an advanced, evidence-based molecular profiling service for patients with non-small cell lung cancer (NSCLC), melanoma, and cancers of the breast, colon and ovary. In addition, the company has enhanced the...
IRVING, Texas, June 3, 2012 /PRNewswire/ -- Caris Life Sciences(®), a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling and blood-based diagnostic services, announces the upcoming introduction of Caris Target Now Select((TM)), an advanced, evidence-based molecular profiling service for patients with cancers of the breast, colon, and ovary, non-small cell lung cancer (NSCLC), and melanoma. The new service...
